Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Asa3.0
Aspirin (niedrig dosiert) – Forschung
Überwiegend Mechanismus / Beobachtung
35 begutachtete Studien
Was die Evidenz sagt
Überwiegend Mechanismus / Beobachtung
Die meisten Studien zu Aspirin (niedrig dosiert) sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.
Die meiste Evidenz stammt aus hochwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 2009–2026 mit einer typischen Studiengröße von 410 Teilnehmenden.
Basierend auf 35 Studien · 11 Meta-Analysen · 7 RCTs · 210,922 Teilnehmende insgesamt
Konfidenz
Hohe Konfidenz
Nach Outcome
Safety profile
Überwiegend Mechanismus / Beobachtung14 Studien
Cardiovascular preventionReduziert nachweislich wiederkehrende kardiovaskuläre Ereignisse bei Personen mit bestehender Herz-Kreislauf-Erkrankung (Sekundärprävention; bei gesunden älteren Erwachsenen wurde kein Nutzen gezeigt) · Fortlaufende tägliche Einnahme
Überwiegend Mechanismus / Beobachtung13 Studien
Healthy aging & mortality
Überwiegend Mechanismus / Beobachtung3 Studien
Aktives Forschungsgebiet
29 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2026
200920172026
1Meta-Analysen=5,459 · very large study2026
Trials are needed to determine whether specific antithrombotic strategies meaningfully improve outcomes in this high-risk population.
Rothstein A, Khazaal O, Messe SR, Liu Y, Hennessy S, Chen Y, Algra A, Uchiyama S, Poli S, Geisler T, Serna Higuita LM, Perera KS, Taylor A, Kasner SE. · Stroke (2026)
Switching to another therapy was associated with a pooled relative risk of recurrent stroke of 0.88 (95% CI, 0.76-1.03) compared with continuing aspirin, with minimal heterogeneity ( P =0.93; I ²=0).
For the composite secondary outcome, 6 studies contributed data, yielding a pooled relative risk of 0.89 (95% CI, 0.72-1.10).
In the network meta-analysis, dabigatran, apixaban, and aspirin+low-dose rivaroxaban ranked the highest among antithrombotic alternatives to aspirin, though none were significantly better than continuing aspirin.
It remains unclear if LDA has the same benefit/risk profile in all aPL profile, i.e. single, double, or triple positivity.
De Pascali F, Filippova YA, Donadini MP, Pengo V, Squizzato A. · Thrombosis research (2025)
The differences in the outcomes among groups were estimated as pooled odds ratio (OR) and corresponding 95 % confidence interval (CI).
Thrombotic events were significantly reduced in the LDA group compared to the control group [OR 0.46 (95 % CI 0.30-0.71), I2 27%, fixed-effects model].
Arterial thrombotic events were significantly reduced in the LDA group compared to the control group [OR 0.47 (95 % CI 0.26-0.86), I2 0%, fixed-effects model].
Trial registration number EU CTIS: 2023-504553-12-01.
Hovsepjan V, Thijs A, van Diemen JJK, Bogaards JA, Winter MM, Bosmans JE, Prins JM, ASCAP study group. · BMJ open (2025)
Assuming an average baseline ACS risk of 7.5% over 180 days with up to 30% variation across strata, and a 60% hazard reduction due to aspirin, the required sample size to achieve 80% power is 760 patients.
Currently, 114 patients are enrolled in the study.
Ethics and dissemination This study is approved by the Medical Ethics Committee Amsterdam UMC (Amsterdam, The Netherlands) under reference number 2023.0741 and registered under EU trial number 2023-504553-12-01 in the EU portal CTIS (Clinical Trials Information System).
These findings support biomarker-driven strategies and highlight the need for ongoing trials to validate long-term efficacy and safety.
Lenz G, Pereira RA, Valagni G, Biachi de Castria T. · Clinical colorectal cancer (2025)
Anti-inflammatory therapy improved DFS (HR = 0.85; 95% CI: 0.76-0.96; P = .008) and TTR (HR = 0.61; 95% CI: 0.44-0.84; P = .003) but not OS (HR = 0.90; P = .07) or recurrence rates (RR = 0.90; P = .06).
Aspirin demonstrated superior DFS benefit (HR = 0.70; P = .03) and patients with PI3K mutations had markedly reduced recurrence risk (HR = 0.56; P < .0001).
Serious cardiac events, gastrointestinal bleeding, and infections showed no significant differences.
Further research is warranted to guide clinical decision-making regarding acetylsalicylic acid therapy in this population.
Agudelo-Arrieta M, Marin-Navas F, Alonso-Ramirez AC, Taub-Krivoy A, Sierra-Peña JA, Feo-Lee OH, Berbeo-Calderon ME. · Acta neurochirurgica (2025)
Results The systematic review included eight cohort studies (seven retrospective, one prospective) and one RCT, comprising a total of 3,209 participants, of whom 1,152 (35.8%) had received acetylsalicylic acid preoperatively.
Our meta-analysis of 1556 observations found no significant difference in recurrence risk between acetylsalicylic acid users and non-users [RR: 0.99; 95% CI: 0.68-1.45; p = 0.96; I 2 = 11.2%].
However, preoperatively acetylsalicylic acid use was associated with a significantly increased risk of thromboembolic events [RR: 2.89; 95% CI: 1.18-7.11; p = 0.02; I 2 = 0.0%].
Although our findings should be carefully interpreted because of the limited data, they indicate that aspirin may be more effective than warfarin in East Asian patients, underscoring the need for further research into ethnicity-tailored thromboprophylaxis strategies.
Oh KJ et al. · Pediatric cardiology (2026)
In the East Asian subgroup, aspirin significantly decreased thromboembolic risk, compared with no intervention (RR, 0.31; 95% CI, 0.16-0.58; p < 0.001), and was significantly more effective than warfarin (RR, 0.57; 95% CI, 0.37-0.88; p = 0.01).
Bleeding risk showed no significant between-group differences.
Compared with no intervention, thromboprophylaxis in patients with Fontan circulation reduces thromboembolic risk.
Pregnancy in kidney transplant recipients is challenging due to maternal and perinatal risks.
Santos ACM et al. · Jornal brasileiro de nefrologia (2026)
Pregnancy in kidney transplant recipients is challenging due to maternal and perinatal risks.
However, the present review demonstrates that clinical and obstetric management by an experienced multidisciplinary team contributes to better maternal and perinatal outcomes in pregnancies among kidney transplant recipients.
The findings of this narrative review underscore the need for further research to focus on identifying high-risk biomarkers, genetic predispositions, and safer alternatives to improve evidence-based guidelines and reduce morbidity and mortality in paediatric intensive care.
Beckers L, Verbruggen J, Saldien V, De Dooy J, van Zanten E, Peros T, Wiggelinkhuizen M, Jorens PG. · Children (Basel, Switzerland) (2026)
Clinicians must carefully consider the risks and benefits of these drugs.
To minimise adverse events, strict monitoring, dose adjustments, and the use of safer alternatives are essential.
However, it appears that their use in well-defined circumstances in acute illness in children is still warranted.
These findings suggest that the PRECISE-DAPT score may serve as a multidimensional prognostic tool beyond bleeding risk stratification.
Uğuz B, Öz A, Kertmen Ö, Çetin İ, Bekar L, Böyük F, Asil S, Cansel M, Taşolar H, Zoghi M. · Cardiovascular journal of Africa (2026)
Results Of 1,500 patients, 344 (22.9%) had a PRECISE-DAPT score ≥ 25.
Compared with patients with a PRECISE-DAPT score < 25, those with a PRECISE-DAPT score ≥ 25 were older (mean age 71.9 vs. 60.8 years; p < 0.001), more frequently female, and had significantly more comorbidities and reduced LVEF.
At 6 months, patients with a PRECISE-DAPT score ≥ 25 experienced higher rates of all-cause hospitalisation (19.5% vs. 10.9%; p < 0.001), cardiovascular hospitalisation (11.6% vs. 6.7%; p = 0.003), stent thrombosis (2.6% vs. 1.0%; p = 0.029), and BARC type 1 bleeding (7.5% vs. 2.2%; p < 0.001).
Conclusion While VTE prophylaxis regimens are typically based on institutional guidelines or surgeon preference, the proposed algorithm can help guide providers in prescribing a treatment modality for patients who may not benefit from existing regimens.
Layne E. · Orthopedic nursing (2026)
Results It was concluded that there is no statistically significant difference between acetylsalicylic acid and anticoagulant use in the prevention of VTEs in postoperative TJA patients.
Articles were included if they utilized both antiplatelets and anticoagulants, included both total hip arthroplasty and total knee arthroplasty patients, and analyzed VTE occurrence as a subject of interest.
An algorithm was developed based on clinical findings, medication parameters, and current guidelines to assist in determining the best antithrombotic medication for a patient.
Canonico ME, Parr J, Debus ES, Nehler MR, Patel MR, Anand SS, Svet M, Hess CN, Capell WH, Ycas J, Chen J, Szarek M, Muehlhofer E, Haskell LP, Berkowitz SD, Bauersachs RM, Bonaca MP. · Circulation. Cardiovascular interventions (2026)
The VOYAGER-PAD trial (Vascular Outcomes Study of Acetylsalicylic Acid Along With Rivaroxaban in Endovascular or Surgical Limb Revascularization for Peripheral Artery Disease) demonstrated that rivaroxaban 2.5 mg twice daily on top of antiplatelet therapy significantly reduced this risk.
Results A total of 6564 patients were enrolled with 2336 (35.5%) having a prior history of LER.
Patients with a history of prior LER had a higher rate of MALE relative to those without prior LER (3-year Kaplan-Meier cumulative rates, 12.9% versus 8.0%; hazard ratio [HR], 1.58 [95% CI, 1.25-1.99]).
Finally, we discuss future perspectives, including the potential of liquid biopsy-based methylation profiling and advanced sequencing technologies to improve PitNET classification, prognostication, and therapeutic stratification in the near future.
Szabó B et al. · Endocrine-related cancer (2026)
Failure to resolve these cytosine modifications may, therefore, obscure biologically relevant mechanisms and may contribute to inconsistent findings across studies.
This mini-review critically examines the DNA methylation-demethylation cycle in PitNETs, discusses the challenges of accurately detecting cytosine modifications, and summarises the emerging evidence, linking altered demethylation dynamics to tumour differentiation, proliferation, and aggressiveness.
We also highlight the therapeutic relevance of targeting epigenetic regulators, such as DNA methyltransferases, TET enzymes, and associated co-factors, and review data supporting both traditional epigenetic drugs and repurposed agents.
The assessment should be performed transabdominally, using standardized techniques and the mean pulsatility index, and should be conducted by trained and audited professionals.
Pimentel RCG et al. · Best practice & research. Clinical obstetrics & gynaecology (2026)
This condition affects up to 15% of pregnancies and contributes to preeclampsia, fetal growth restriction, and preterm delivery, leading causes of preventable perinatal morbidity and mortality.
Uterine artery Doppler, ideally performed in the first trimester, should be incorporated into a competing risks algorithm to identify pregnant women at high risk for preeclampsia, enabling early prevention with acetylsalicylic acid, ideally before 16 weeks.
The assessment should be performed transabdominally, using standardized techniques and the mean pulsatility index, and should be conducted by trained and audited professionals.
In the adjusted analysis, there was no difference in the SOFA change between the groups (mean placebo to ASA group difference, 0.60; 95% CI, -0.55 to 1.75; p = 0.30).
In the intervention group, there were a higher number of serious adverse events (9 [11%] vs. 1 [1.2%]; p = 0.009) and major bleeding (8 [8.5%] vs. 1 [1.2%]; p = 0.02).
There were no differences in any of the secondary outcomes.
Since postoperative complications, preoperative hypertension, and preoperative antiplatelet therapy are modifiable, LOS can serve as a quality parameter for CEA and CAS.
Lehmann S, Hoene A, Golbach R, Epple J, Debus ES, Grundmann RT. · Annali italiani di chirurgia (2025)
In total, 3,952,240 CEA patients (59.14% male, 40.86% female) and 201,937 CAS patients (62% male, 38% female) were included.
Of the CEA patients, 77.93% were asymptomatic, compared to 63% of CAS patients (p = 0.671).
The LOS was 2.04 days for CEA and 2.52 days for CAS (p = 0.399).